Saturday, February 21, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Banking & Insurance

XRP’s On-Chain Activity Plummets Despite Ripple’s Institutional Progress

SiterGedge by SiterGedge
February 21, 2026
in Banking & Insurance, Blockchain, Ethereum & Altcoins
0
XRP Stock
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

A significant expansion of Deutsche Bank’s collaboration with Ripple Labs marks a milestone for the blockchain firm, highlighting growing institutional adoption of its technology. However, a closer examination reveals a critical divergence: the banking giant is implementing Ripple’s blockchain solutions but is not utilizing the XRP cryptocurrency within its operations. This distinction comes as activity on the XRP network itself experiences a severe contraction.

Network Engagement Crashes

Data from blockchain analyst Ali Martinez underscores a stark decline in user engagement on the XRP ledger. Over a seven-day period, the number of active addresses plummeted by approximately 26%, falling from 55,080 to 40,778. This sharp drop signals waning interest from retail participants and points to decreasing transaction volumes on the network. The positive news flow surrounding corporate partnerships is not reflected in the on-chain metrics, revealing a disconnect between institutional deals and ecosystem vitality.

Adoption Without the Asset

Deutsche Bank’s strategy focuses on leveraging Ripple’s enterprise-grade, blockchain-based software to modernize legacy payment infrastructures. The objectives are to reduce settlement times from days to seconds and to cut operational costs for cross-border transfers by up to 30%.

Should investors sell immediately? Or is it worth buying XRP?

Critically, this partnership utilizes Ripple’s private ledger technology and enterprise software suite. It does not employ the “On-Demand Liquidity” service, which specifically uses XRP as a bridge currency for liquidity. The bank is facilitating fiat-to-fiat transactions via blockchain rails, completely bypassing the need for the XRP token. For investors, this delineation is crucial—institutional acceptance of the underlying technology does not inherently translate into direct demand for the associated digital asset.

Price Feels the Strain

The growing chasm between technological adoption and token utility is applying downward pressure on XRP’s market valuation. The cryptocurrency has breached a key support level at $1.50 and is currently trading around $1.42. Market experts note that major financial institutions, including Standard Chartered, have revised their long-term price targets for XRP downward. This trend is viewed as evidence that the market is increasingly distinguishing between Ripple’s success as a software provider and the fundamental demand drivers for the XRP token.

Ad

XRP Stock: Buy or Sell?! New XRP Analysis from February 21 delivers the answer:

The latest XRP figures speak for themselves: Urgent action needed for XRP investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 21.

XRP: Buy or sell? Read more here...

Tags: XRP
SiterGedge

SiterGedge

Related Posts

Beeline Holdings Stock
Analysis

Beeline Holdings Charts Aggressive Revenue Target with Strategic Hire

February 20, 2026
iShares MSCI Pacific ex Japan ETF Stock
Analysis

Pacific Ex-Japan ETF Approaches All-Time High

February 20, 2026
Coinbase Stock
Blockchain

Coinbase’s Billion-Dollar Buyback Provides Critical Share Price Support

February 20, 2026
Next Post
GRI Bio Stock

GRI Bio's Financial Runway Extends to 2027 Amid Clinical Push

Tilray Stock

Tilray Secures Exclusive U.S. Rights for Carlsberg Beer Portfolio

Ultragenyx Pharmaceutical Stock

Divergent Analyst Views Highlight Ultragenyx's Crossroads

Recommended

Honeywell Stock

Honeywell’s Dividend Dilemma: A Mixed Blessing for Shareholders

3 months ago
Realty Income Stock

Institutional Capital Flows Signal Renewed Confidence in Realty Income

4 months ago
Voestalpine Stock

Voestalpine’s Strategic Digital Investment Signals Long-Term Strength

1 month ago
National Health Investors Stock

A Strategic Outperformer in Senior Housing Real Estate

6 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

XRP’s On-Chain Activity Plummets Despite Ripple’s Institutional Progress

Volatus Aerospace Charts Defense Sector Expansion Following Stellar Market Performance

Benitec Biopharma: A Critical Regulatory Path Emerges for 2026

Regulatory Scrutiny and Rival Bids Weigh on Netflix’s Acquisition Ambitions

Alkaline Water Company Seeks Revival Through Core Market Refocus

Madison Square Garden Entertainment: Post-Holiday Strategy Takes Center Stage

Trending

Ultragenyx Pharmaceutical Stock
Analysis

Divergent Analyst Views Highlight Ultragenyx’s Crossroads

by SiterGedge
February 21, 2026
0

Shares of Ultragenyx Pharmaceutical are navigating a period of significant uncertainty, caught between robust revenue growth and...

Tilray Stock

Tilray Secures Exclusive U.S. Rights for Carlsberg Beer Portfolio

February 21, 2026
GRI Bio Stock

GRI Bio’s Financial Runway Extends to 2027 Amid Clinical Push

February 21, 2026
XRP Stock

XRP’s On-Chain Activity Plummets Despite Ripple’s Institutional Progress

February 21, 2026
Volatus Aerospace Stock

Volatus Aerospace Charts Defense Sector Expansion Following Stellar Market Performance

February 21, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Divergent Analyst Views Highlight Ultragenyx’s Crossroads
  • Tilray Secures Exclusive U.S. Rights for Carlsberg Beer Portfolio
  • GRI Bio’s Financial Runway Extends to 2027 Amid Clinical Push

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com